Guendalina Zuccari
Overview
Explore the profile of Guendalina Zuccari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alfei S, Zuccari G
Nanomaterials (Basel)
. 2025 Feb;
15(4).
PMID: 39997828
Currently, nanotechnology is the most promising science, engineering, and technology conducted at the nanoscale (nm), which is used in several sectors. Collectively, nanotechnology is causing a new industrial revolution, and...
2.
Alfei S, Zuccari G
Int J Mol Sci
. 2025 Jan;
26(2).
PMID: 39859559
Oxidative stress (OS), generated by the overrun of reactive species of oxygen and nitrogen (RONS), is the key cause of several human diseases. With inflammation, OS is responsible for the...
3.
Baldassari S, Yan M, Ailuno G, Zuccari G, Bassi A, Vernazza S, et al.
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458670
Background/objectives: Three-dimensional (3D) cell culture technologies allow us to overcome the constraints of two-dimensional methods in different fields like biochemistry and cell biology and in pharmaceutical in vitro tests. In...
4.
Neduri K, Ailuno G, Zuccari G, Bassi A, Vernazza S, Schito A, et al.
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458669
Background/objectives: Oral diseases causing mucosal lesions are normally treated with local or systemic anti-inflammatory, analgesic and antimicrobial agents. The development of topical formulations, including wound-healing promoters, might speed up the...
5.
Alfei S, Zuccari G, Athanassopoulos C, Domenicotti C, Marengo B
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337557
Cutaneous metastatic melanoma (CMM) is the most aggressive form of skin cancer with a poor prognosis. Drug-induced secondary tumorigenesis and the emergency of drug resistance worsen an already worrying scenario,...
6.
Alfei S, Giannoni P, Signorello M, Torazza C, Zuccari G, Athanassopoulos C, et al.
Nanomaterials (Basel)
. 2024 Sep;
14(18).
PMID: 39330662
Neuroblastoma (NB) is a solid tumor occurring in infancy and childhood. Its high-risk form has currently a survival rate <50%, despite aggressive treatments. This worrying scenario is worsened by drug-induced...
7.
Zuccari G, Zorzoli A, Marimpietri D, Alfei S
Curr Drug Deliv
. 2024 Sep;
PMID: 39229999
Introduction/objectives: The purpose of the study was to evaluate the suitability of mixed micelles prepared with D-α-tocopheryl polyethylene glycol succinate (TPGS) and 1,2- distearoyl-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (DSPE-PEG) to encapsulate the poorly soluble...
8.
Alfei S, Zuccari G, Bacchetti F, Torazza C, Milanese M, Siciliano C, et al.
Nanomaterials (Basel)
. 2024 Aug;
14(16).
PMID: 39195389
The increasing emergence of multidrug-resistant (MDR) pathogens due to antibiotic misuse translates into obstinate infections with high morbidity and high-cost hospitalizations. To oppose these MDR superbugs, new antimicrobial options are...
9.
Alfei S, Schito G, Schito A, Zuccari G
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000290
The increasing emergence of multidrug-resistant (MDR) pathogens causes difficult-to-treat infections with long-term hospitalizations and a high incidence of death, thus representing a global public health problem. To manage MDR bacteria...
10.
Alfei S, Zuccari G
Pharmaceutics
. 2024 May;
16(5).
PMID: 38794242
The development of numerous drugs is often arrested at clinical testing stages, due to their unfavorable biopharmaceutical characteristics. It is the case of fenretinide (4-HPR), a second-generation retinoid, that demonstrated...